Belvedere Trading
AKRO

Belvedere Trading’s Akero Therapeutics AKRO Stock Holding History

Belvedere Trading’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-1,758
Closed -$81.9K – 630
2023
Q2 		$82.1K Buy
+1,758
New +$80.6K ﹤0.01% 467
2022
Q4 		– Sell
-18,394
Closed -$808K – 1126
2022
Q3 		$808K Buy
+18,394
New +$281K 0.03% 48

Other funds holding AKRO

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Belvedere Trading's AKRO Position: Q3 2023 in Review

Belvedere Trading sold out of Akero Therapeutics (AKRO) in Q3 2023, closing a stake of 1,758 shares — an estimated $81.9K sold.

Belvedere Trading first reported a position in AKRO in Q3 2022 and held it in 2 quarters. The position peaked at $808K in Q3 2022. 181 funds tracked by Wall St. Rank hold AKRO as of Q3 2023.

  • Belvedere Trading reported no remaining Akero Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Belvedere Trading sold 1,758 Akero Therapeutics shares in Q3 2023, an estimated $81.9K.
  • Belvedere Trading first reported a position in Akero Therapeutics in Q3 2022 and held it in 2 quarters.
  • Belvedere Trading's Akero Therapeutics position peaked at $808K in Q3 2022.
  • 181 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2023.

Based on Belvedere Trading's 13F filing for Q3 2023, filed 27 Oct 2023.